Difference between revisions of "Prednisolone (Millipred)"
Jump to navigation
Jump to search
m |
|||
| Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Acquired | + | *[[Acquired hemophilia A]] |
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
| Line 50: | Line 50: | ||
[[Category:Chronic lymphocytic leukemia medications]] | [[Category:Chronic lymphocytic leukemia medications]] | ||
| − | [[Category:Acquired | + | [[Category:Acquired hemophilia A medications]] |
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
Revision as of 23:19, 6 November 2023
General information
Class/mechanism: Corticosteroid, glucocorticoid.[1][2][3]
Route: PO, gtt (ophthalmic eye drops)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acquired hemophilia A
- B-cell acute lymphoblastic leukemia
- Breast cancer
- Burkitt lymphoma
- Chronic lymphocytic leukemia
- Diffuse large B-cell lymphoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Follicular lymphoma
- Classical Hodgkin lymphoma
- Langerhans cell histiocytosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Prostate cancer
Diseases for which it was used
Patient drug information
- Prednisolone (Millipred) patient drug information (Chemocare)[4]
- Prednisolone (Millipred) patient drug information (UpToDate)[5]
History of changes in EMA indication
- 1956-07-13: EURD
History of changes in PMDA indication
- 2011-09-16: New indication for the treatment of multiple myeloma.
- 2015-06-26: revised indications and a new dosage for the treatment of malignant lymphoma and similar diseases (closely-related diseases).
Also known as
- Generic names: delta(1)hydrocortisone, delta1-dehydro-hydrocortisone, deltahydrocortisone, metacortandralone, prednisolone acetate, prednisolone tebutate
- Brand names: Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Cotolone, Dacortin H, Decaprednil, Decortin H, Delta-Cortef, Deltacortril, Delta-Diona, Delta-Phoricol, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Medicort, Meticortelone, Meti-derm, Millipred, Opredsone, Orapred, Panafcortelone, Predcor, Predicort, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Prednicortelone, Predni-Helvacort, Predonine, Prelone, Prenilone, Pri-Cortin, Veripred
References
Categories:
- Drugs
- Oral medications
- Steroids
- Immunosuppressants
- Chronic lymphocytic leukemia medications
- Acquired hemophilia A medications
- B-cell acute lymphoblastic leukemia medications
- Breast cancer medications
- Burkitt lymphoma medications
- Diffuse large B-cell lymphoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Classical Hodgkin lymphoma medications
- Langerhans cell histiocytosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Multiple myeloma medications
- Prostate cancer medications
- Acute myeloid leukemia medications (historic)
- FDA approved in 1955
- EMA approved in 1956
- PMDA approved drugs
- WHO Essential Cancer Medicine